These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11157014)

  • 1. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.
    Eppenberger-Castori S; Kueng W; Benz C; Caduff R; Varga Z; Bannwart F; Fink D; Dieterich H; Hohl M; Müller H; Paris K; Schoumacher F; Eppenberger U
    J Clin Oncol; 2001 Feb; 19(3):645-56. PubMed ID: 11157014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
    Thor AD; Liu S; Edgerton S; Moore D; Kasowitz KM; Benz CC; Stern DF; DiGiovanna MP
    J Clin Oncol; 2000 Sep; 18(18):3230-9. PubMed ID: 10986055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of ERBB family mRNA expression in breast carcinomas.
    Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
    Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
    Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
    Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.
    Quaranta M; Daniele A; Coviello M; Savonarola A; Abbate I; Venneri MT; Paradiso A; Stea B; Zito A; Labriola A; Schittulli F
    Tumori; 2006; 92(4):311-7. PubMed ID: 17036522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
    Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
    J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-erbB-2 status is an independent predictor of survival after first recurrence.
    Horiguchi J; Iino Y; Takei H; Maemura M; Takeyoshi I; Yokoe T; Ohwada S; Oyama T; Nakajima T; Morishita Y
    Int J Oncol; 1998 Jan; 12(1):123-8. PubMed ID: 9454895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.
    Sjögren S; Inganäs M; Lindgren A; Holmberg L; Bergh J
    J Clin Oncol; 1998 Feb; 16(2):462-9. PubMed ID: 9469329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical study of c-erbB-2 expression in primary breast cancer.
    Chearskul S; Onreabroi S; Churintrapun M; Semprasert N; Bhothisuwan K
    Asian Pac J Allergy Immunol; 2001 Sep; 19(3):197-205. PubMed ID: 11826915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
    Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F
    Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic relevance of androgen receptor detection in operable breast cancer.
    Søiland H; Kørner H; Skaland I; Janssen EA; Gudlaugsson E; Varhaug JE; Baak JP; Søreide JA
    J Surg Oncol; 2008 Dec; 98(7):551-8. PubMed ID: 18937259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.